Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use

Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to de...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-06, Vol.18 (6), p.1190
Main Authors: Gimona, Mario, Pachler, Karin, Laner-Plamberger, Sandra, Schallmoser, Katharina, Rohde, Eva
Format: Article
Language:English
Subjects:
Animals
Biological activity
Biological products
Biological Products - isolation & purification
Biological Products - pharmacology
Biological Products - therapeutic use
Cancer therapies
Cell Fractionation - methods
Cell Fractionation - standards
Cell-Derived Microparticles
Clinical trials
Disease
Drug development
Drug dosages
Epidermolysis bullosa
Exosomes
Extracellular Vesicles
Good Manufacturing Practice
Humans
Manufacturing
Mesenchyme
Opinion
Progenitor cells
Skin
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043
cites cdi_FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043
container_end_page
container_issue 6
container_start_page 1190
container_title International journal of molecular sciences
container_volume 18
creator Gimona, Mario
Pachler, Karin
Laner-Plamberger, Sandra
Schallmoser, Katharina
Rohde, Eva
description Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to develop safe and efficacious therapies, whilst taking into account the applicable regulations. Here, we discuss the requirements for manufacturing, safety, and efficacy testing of EVs along their path from the laboratory to the patient. Development of EV-therapeutics is influenced by the source cell types and the target diseases. In this article, we express our view based on our experience in manufacturing biological therapeutics for routine use or clinical testing, and focus on strategies for advancing mesenchymal stromal cell (MSC)-derived EV-based therapies. We also discuss the rationale for testing MSC-EVs in selected diseases with an unmet clinical need such as critical size bone defects, epidermolysis bullosa and spinal cord injury. While the scientific community, pharmaceutical companies and clinicians are at the point of entering into clinical trials for testing the therapeutic potential of various EV-based products, the identification of the mode of action underlying the suggested potency in each therapeutic approach remains a major challenge to the translational path.
doi_str_mv 10.3390/ijms18061190
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5486013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1907000086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043</originalsourceid><addsrcrecordid>eNpdkc1LAzEQxYMotlZvnmXBiwdX87GbZi-ClmqFih5aryHNTtqU_ajJRvS_d0trqc5lBubHY948hM4JvmEsw7d2WXoiMCckwweoSxJKY4x5_3Bv7qAT75cYU0bT7Bh1qEhFnxLaRW8vqgpG6SY4W82j2kSjUKoqGn41TmkoilAoF72Dt7qA-EF5yKPJApxaQWis9pGpXTQobGW1KqKph1N0ZFTh4Wzbe2j6OJwMRvH49el5cD-OdUJoE2c59MksB6pwrmYJBZFRzDTjinLCUs21BiIYN2CIwibhOptRk4icYUYAJ6yH7ja6qzArIddQtQcXcuVsqdy3rJWVfzeVXch5_SnTRHBMWCtwtRVw9UcA38jS-rVjVUEdvGzf2cdtCd6il__QZR1c1dqTlIuUZokQa8HrDaVd7b0DszuGYLmOSu5H1eIX-wZ28G827AeX7JAc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685294883</pqid></control><display><type>article</type><title>Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content (ProQuest)</source><creator>Gimona, Mario ; Pachler, Karin ; Laner-Plamberger, Sandra ; Schallmoser, Katharina ; Rohde, Eva</creator><creatorcontrib>Gimona, Mario ; Pachler, Karin ; Laner-Plamberger, Sandra ; Schallmoser, Katharina ; Rohde, Eva</creatorcontrib><description>Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to develop safe and efficacious therapies, whilst taking into account the applicable regulations. Here, we discuss the requirements for manufacturing, safety, and efficacy testing of EVs along their path from the laboratory to the patient. Development of EV-therapeutics is influenced by the source cell types and the target diseases. In this article, we express our view based on our experience in manufacturing biological therapeutics for routine use or clinical testing, and focus on strategies for advancing mesenchymal stromal cell (MSC)-derived EV-based therapies. We also discuss the rationale for testing MSC-EVs in selected diseases with an unmet clinical need such as critical size bone defects, epidermolysis bullosa and spinal cord injury. While the scientific community, pharmaceutical companies and clinicians are at the point of entering into clinical trials for testing the therapeutic potential of various EV-based products, the identification of the mode of action underlying the suggested potency in each therapeutic approach remains a major challenge to the translational path.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms18061190</identifier><identifier>PMID: 28587212</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Biological activity ; Biological products ; Biological Products - isolation &amp; purification ; Biological Products - pharmacology ; Biological Products - therapeutic use ; Cancer therapies ; Cell Fractionation - methods ; Cell Fractionation - standards ; Cell-Derived Microparticles ; Clinical trials ; Disease ; Drug development ; Drug dosages ; Epidermolysis bullosa ; Exosomes ; Extracellular Vesicles ; Good Manufacturing Practice ; Humans ; Manufacturing ; Mesenchyme ; Opinion ; Progenitor cells ; Skin ; Stem cells</subject><ispartof>International journal of molecular sciences, 2017-06, Vol.18 (6), p.1190</ispartof><rights>2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 by the authors. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043</citedby><cites>FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043</cites><orcidid>0000-0002-1416-6023</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2685294883/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2685294883?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28587212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gimona, Mario</creatorcontrib><creatorcontrib>Pachler, Karin</creatorcontrib><creatorcontrib>Laner-Plamberger, Sandra</creatorcontrib><creatorcontrib>Schallmoser, Katharina</creatorcontrib><creatorcontrib>Rohde, Eva</creatorcontrib><title>Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to develop safe and efficacious therapies, whilst taking into account the applicable regulations. Here, we discuss the requirements for manufacturing, safety, and efficacy testing of EVs along their path from the laboratory to the patient. Development of EV-therapeutics is influenced by the source cell types and the target diseases. In this article, we express our view based on our experience in manufacturing biological therapeutics for routine use or clinical testing, and focus on strategies for advancing mesenchymal stromal cell (MSC)-derived EV-based therapies. We also discuss the rationale for testing MSC-EVs in selected diseases with an unmet clinical need such as critical size bone defects, epidermolysis bullosa and spinal cord injury. While the scientific community, pharmaceutical companies and clinicians are at the point of entering into clinical trials for testing the therapeutic potential of various EV-based products, the identification of the mode of action underlying the suggested potency in each therapeutic approach remains a major challenge to the translational path.</description><subject>Animals</subject><subject>Biological activity</subject><subject>Biological products</subject><subject>Biological Products - isolation &amp; purification</subject><subject>Biological Products - pharmacology</subject><subject>Biological Products - therapeutic use</subject><subject>Cancer therapies</subject><subject>Cell Fractionation - methods</subject><subject>Cell Fractionation - standards</subject><subject>Cell-Derived Microparticles</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Epidermolysis bullosa</subject><subject>Exosomes</subject><subject>Extracellular Vesicles</subject><subject>Good Manufacturing Practice</subject><subject>Humans</subject><subject>Manufacturing</subject><subject>Mesenchyme</subject><subject>Opinion</subject><subject>Progenitor cells</subject><subject>Skin</subject><subject>Stem cells</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkc1LAzEQxYMotlZvnmXBiwdX87GbZi-ClmqFih5aryHNTtqU_ajJRvS_d0trqc5lBubHY948hM4JvmEsw7d2WXoiMCckwweoSxJKY4x5_3Bv7qAT75cYU0bT7Bh1qEhFnxLaRW8vqgpG6SY4W82j2kSjUKoqGn41TmkoilAoF72Dt7qA-EF5yKPJApxaQWis9pGpXTQobGW1KqKph1N0ZFTh4Wzbe2j6OJwMRvH49el5cD-OdUJoE2c59MksB6pwrmYJBZFRzDTjinLCUs21BiIYN2CIwibhOptRk4icYUYAJ6yH7ja6qzArIddQtQcXcuVsqdy3rJWVfzeVXch5_SnTRHBMWCtwtRVw9UcA38jS-rVjVUEdvGzf2cdtCd6il__QZR1c1dqTlIuUZokQa8HrDaVd7b0DszuGYLmOSu5H1eIX-wZ28G827AeX7JAc</recordid><startdate>20170603</startdate><enddate>20170603</enddate><creator>Gimona, Mario</creator><creator>Pachler, Karin</creator><creator>Laner-Plamberger, Sandra</creator><creator>Schallmoser, Katharina</creator><creator>Rohde, Eva</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1416-6023</orcidid></search><sort><creationdate>20170603</creationdate><title>Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use</title><author>Gimona, Mario ; Pachler, Karin ; Laner-Plamberger, Sandra ; Schallmoser, Katharina ; Rohde, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Biological activity</topic><topic>Biological products</topic><topic>Biological Products - isolation &amp; purification</topic><topic>Biological Products - pharmacology</topic><topic>Biological Products - therapeutic use</topic><topic>Cancer therapies</topic><topic>Cell Fractionation - methods</topic><topic>Cell Fractionation - standards</topic><topic>Cell-Derived Microparticles</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Epidermolysis bullosa</topic><topic>Exosomes</topic><topic>Extracellular Vesicles</topic><topic>Good Manufacturing Practice</topic><topic>Humans</topic><topic>Manufacturing</topic><topic>Mesenchyme</topic><topic>Opinion</topic><topic>Progenitor cells</topic><topic>Skin</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gimona, Mario</creatorcontrib><creatorcontrib>Pachler, Karin</creatorcontrib><creatorcontrib>Laner-Plamberger, Sandra</creatorcontrib><creatorcontrib>Schallmoser, Katharina</creatorcontrib><creatorcontrib>Rohde, Eva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gimona, Mario</au><au>Pachler, Karin</au><au>Laner-Plamberger, Sandra</au><au>Schallmoser, Katharina</au><au>Rohde, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2017-06-03</date><risdate>2017</risdate><volume>18</volume><issue>6</issue><spage>1190</spage><pages>1190-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Extracellular vesicles (EVs) derived from stem and progenitor cells may have therapeutic effects comparable to their parental cells and are considered promising agents for the treatment of a variety of diseases. To this end, strategies must be designed to successfully translate EV research and to develop safe and efficacious therapies, whilst taking into account the applicable regulations. Here, we discuss the requirements for manufacturing, safety, and efficacy testing of EVs along their path from the laboratory to the patient. Development of EV-therapeutics is influenced by the source cell types and the target diseases. In this article, we express our view based on our experience in manufacturing biological therapeutics for routine use or clinical testing, and focus on strategies for advancing mesenchymal stromal cell (MSC)-derived EV-based therapies. We also discuss the rationale for testing MSC-EVs in selected diseases with an unmet clinical need such as critical size bone defects, epidermolysis bullosa and spinal cord injury. While the scientific community, pharmaceutical companies and clinicians are at the point of entering into clinical trials for testing the therapeutic potential of various EV-based products, the identification of the mode of action underlying the suggested potency in each therapeutic approach remains a major challenge to the translational path.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>28587212</pmid><doi>10.3390/ijms18061190</doi><orcidid>https://orcid.org/0000-0002-1416-6023</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2017-06, Vol.18 (6), p.1190
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5486013
source PubMed Central (Open Access); Publicly Available Content (ProQuest)
subjects Animals
Biological activity
Biological products
Biological Products - isolation & purification
Biological Products - pharmacology
Biological Products - therapeutic use
Cancer therapies
Cell Fractionation - methods
Cell Fractionation - standards
Cell-Derived Microparticles
Clinical trials
Disease
Drug development
Drug dosages
Epidermolysis bullosa
Exosomes
Extracellular Vesicles
Good Manufacturing Practice
Humans
Manufacturing
Mesenchyme
Opinion
Progenitor cells
Skin
Stem cells
title Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A04%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Manufacturing%20of%20Human%20Extracellular%20Vesicle-Based%20Therapeutics%20for%20Clinical%20Use&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Gimona,%20Mario&rft.date=2017-06-03&rft.volume=18&rft.issue=6&rft.spage=1190&rft.pages=1190-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms18061190&rft_dat=%3Cproquest_pubme%3E1907000086%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-9de71bde2a0dab42e89203c36a26135c6cce1836fef1a0f46c9b2f48d3031e043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2685294883&rft_id=info:pmid/28587212&rfr_iscdi=true